Kovač, MD, PhD, V. et al. 2014. Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. Radiology and Oncology. 48, 4 (Oct. 2014).